NCT06287151

Brief Summary

This study aims to investigate how non-invasive, non-significant risk EMG monitoring can be used intraoperatively to objectively characterize neuraxial anesthesia (i.e. spinal and caudal blockade) in pediatric patients undergoing surgery. The investigators will also attempt to measure the effect of adjunctive intrathecal clonidine on spinal and caudal blockade using EMG. This study also aims to quantify the impact of sevoflurane on basal muscle tone based on EMG changes. This study aims to generate pilot data on this subject to help design future studies.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for not_applicable surgery

Timeline
Completed

Started Aug 2023

Typical duration for not_applicable surgery

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 9, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 20, 2023

Completed
5 months until next milestone

First Posted

Study publicly available on registry

February 29, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2025

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

August 22, 2025

Status Verified

August 1, 2025

Enrollment Period

1.6 years

First QC Date

September 20, 2023

Last Update Submit

August 20, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Determine onset of spinal anesthesia and caudal + general anesthesia using surface EMG as measured by power of signal amplitude.

    Performance of non-invasive surface EMG following administration of regional and/or general anesthesia. This will be assessed by EMG signal amplitude.

    Preoperative placement through resolution of motor blockade in the PACU. Timeframe being day of surgery - up to one day.

  • Determine duration of spinal anesthesia and caudal + general anesthesia using surface EMG as measured by power of signal amplitude. .

    Performance of non-invasive surface EMG following administration of regional and/or general anesthesia. This will be assessed by EMG signal amplitude.

    Preoperative placement through resolution of motor blockade in the PACU. Timeframe being day of surgery - up to one day.

  • Determine density of spinal anesthesia and caudal + general anesthesia using surface EMG as measured by power of signal amplitude.

    Performance of non-invasive surface EMG following administration of regional and/or general anesthesia. This will be assessed by EMG signal amplitude.

    Preoperative placement through resolution of motor blockade in the PACU. Timeframe being day of surgery - up to one day.

  • Determine dermatomal level of spinal anesthesia and caudal + general anesthesia using surface EMG as measured by power of signal amplitude.

    Performance of non-invasive surface EMG following administration of regional and/or general anesthesia. This will be assessed by EMG signal amplitude.

    Preoperative placement through resolution of motor blockade in the PACU. Timeframe being day of surgery - up to one day.

Secondary Outcomes (5)

  • Determine objective effect of clonidine, a common additive to neuraxial blockade in children on the measures described above when SA and CA are used as defined as the onset of SA or CA and measured by the power of signal amplitude.

    Intraoperative time frame through motor blockade in the PACU. Timeframe being day of surgery.

  • Determine objective effect of clonidine, a common additive to neuraxial blockade in children on the measures described above when SA and CA are used as defined as the duration of SA or CA and measured by the power of signal amplitude.

    Intraoperative time frame through motor blockade in the PACU. Timeframe being day of surgery.

  • Determine objective effect of clonidine, a common additive to neuraxial blockade in children on the measures described above when SA and CA are used as defined as the density of SA or CA and measured by the power of signal amplitude.

    Intraoperative time frame through motor blockade in the PACU. Timeframe being day of surgery.

  • Determine objective effect of clonidine, a common additive to neuraxial blockade in children on the measures described above when SA and CA are used as defined as the dermatomal level of SA or CA and measured by the power of signal amplitude.

    Intraoperative time frame through motor blockade in the PACU. Timeframe being day of surgery.

  • Quantify the impact of sevoflurane (%) on basal muscle tone based on EMG signal amplitudes.

    Intraoperative time frame. Timeframe being day of surgery.

Study Arms (6)

General Anesthesia with Penile Block

ACTIVE COMPARATOR

Penile block: prior to the start of surgery 0.5mg/kg of 0.25% bupivacaine w/o epinephrine will be administered GA : Inhalation induction with sevoflurane followed by peripheral IV access, and placement of an endotracheal tube or laryngeal mask airway. No intravenous neuromuscular blockade will be given. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.

Device: BlockSynop surface electromyography device

Spinal Anesthesia with Clonidine

ACTIVE COMPARATOR

Spinal block: 0.5% isobaric bupivacaine with 1:200,000 epinephrine (0.2mL/kg up to 1mL), with or without 1mcg/kg clonidine Clonidine is an FDA approved medication that is commonly administered as an adjunct to SA and CA in this population.

Device: BlockSynop surface electromyography deviceDrug: Clonidine

Spinal Anesthesia without Clonidine

ACTIVE COMPARATOR

Spinal block: 0.5% isobaric bupivacaine with 1:200,000 epinephrine (0.2mL/kg up to 1mL), with or without 1mcg/kg clonidine

Device: BlockSynop surface electromyography device

General Anesthesia with Caudal Anesthesia with Clonidine

ACTIVE COMPARATOR

Caudal block: single-shot caudal injection following induction of GA with 1mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine, with or without clonidine 1mcg/kg Clonidine is an FDA approved medication that is commonly administered as an adjunct to SA and CA in this population.

Device: BlockSynop surface electromyography deviceDrug: ClonidineDrug: Sevoflurane

General Anesthesia with Caudal Anesthesia without Clonidine

ACTIVE COMPARATOR

Caudal block: single-shot caudal injection following induction of GA with 1mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine, with or without clonidine 1mcg/kg

Device: BlockSynop surface electromyography deviceDrug: Sevoflurane

General Anesthesia only

ACTIVE COMPARATOR

GA alone: Inhalation induction with sevoflurane followed by peripheral IV access, and placement of an endotracheal tube or laryngeal mask airway. No intravenous neuromuscular blockade will be given. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.

Device: BlockSynop surface electromyography deviceDrug: Sevoflurane

Interventions

The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.

General Anesthesia onlyGeneral Anesthesia with Caudal Anesthesia with ClonidineGeneral Anesthesia with Caudal Anesthesia without ClonidineGeneral Anesthesia with Penile BlockSpinal Anesthesia with ClonidineSpinal Anesthesia without Clonidine

Clonidine is an alpha-2-agonist which is commonly used as an adjunct in spinal anesthesia and caudal anesthesia to improve both the quality and duration of blockade.

General Anesthesia with Caudal Anesthesia with ClonidineSpinal Anesthesia with Clonidine

5.3. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.

General Anesthesia onlyGeneral Anesthesia with Caudal Anesthesia with ClonidineGeneral Anesthesia with Caudal Anesthesia without Clonidine

Eligibility Criteria

Age0 Years - 5 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Group 1 (GA + penile block): age 5 years or below getting: circumcision or circumcision revision
  • Group 2-5 (SA or GA + CA): age 5 years or below getting: penile or scrotal surgery, inguinal hernia repair, Achilles tendon lengthening, other applicable urological procedures
  • Group 6 (GA only): age 5 years or below getting: operative dentistry, urological or ENT procedures

You may not qualify if:

  • parent refusal
  • systemic infection
  • spine or CNS abnormalities
  • medication allergy
  • adhesive allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

Location

MeSH Terms

Interventions

ClonidineSevoflurane

Intervention Hierarchy (Ancestors)

ImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMethyl EthersEthersOrganic ChemicalsHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbons

Study Officials

  • Grant Heydinger, MD

    Nationwide Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Only the individuals performing data analysis will be blinded to type of anesthetic technique performed.
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Choice of group will be made by attending anesthesiologist based on clinical judgement.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator - MD

Study Record Dates

First Submitted

September 20, 2023

First Posted

February 29, 2024

Study Start

August 9, 2023

Primary Completion

February 28, 2025

Study Completion

December 1, 2025

Last Updated

August 22, 2025

Record last verified: 2025-08

Locations